Literature DB >> 3146762

Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs.

W H Chang1, S S Jaw, H S Wu, L Tsay, E K Yeh.   

Abstract

Striatal homovanillic acid (HVA) levels and drug concentrations in striatum and plasma were examined in guinea pigs after acute and subchronic administrations of haloperidol (HAL) and reduced HAL (RHAL). HVA and drug levels were measured by high performance liquid chromatography with electrochemical detection. HAL and RHAL were interconverted in 10 min. Both maximal HVA responses and peak levels of HAL and RHAL in the striatum were reached at 2 h after injections of both HAL and RHAL. The potency of RHAL in HVA elevation was about one-half that of HAL, consistent with the HAL levels after RHAL and HAL administration. The higher the dose of HAL or RHAL injected, or after repeated injections, the greater the RHAL to HAL ratio produced. In addition, the RHAL to HAL ratios after RHAL were higher than those after HAL. These results suggest that the oxidative drug metabolizing systems are weaker than the reductive processes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146762     DOI: 10.1007/bf00216051

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.

Authors:  W H Chang; T Y Chen; C F Lee; W H Hu; E K Yeh
Journal:  Biol Psychiatry       Date:  1987-11       Impact factor: 13.382

2.  Time-response curves of homovanillic acid in caudate and pre-frontal cortex following acute neuroleptic administration.

Authors:  W H Chang; T Y Chen; E K Yeh
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Quantification of reduced haloperidol and haloperidol by radioimmunoassay.

Authors:  J L Browning; C A Harrington; C M Davis
Journal:  J Immunoassay       Date:  1985

4.  Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain.

Authors:  D G Kirch; M R Palmer; M Egan; R Freedman
Journal:  Neuropharmacology       Date:  1985-05       Impact factor: 5.250

5.  Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection.

Authors:  W H Chang; M Scheinin; R S Burns; M Linnoila
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1983-10

6.  Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.

Authors:  E R Korpi; J E Kleinman; D T Costakos; M Linnoila; R J Wyatt
Journal:  Psychiatry Res       Date:  1984-03       Impact factor: 3.222

7.  Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.

Authors:  L Ereshefsky; C M Davis; C A Harrington; M W Jann; J L Browning; S R Saklad; N R Burch
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

8.  Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration.

Authors:  E R Korpi; D T Costakos; R J Wyatt
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-02

9.  Acute and chronic effects of haloperidol on plasma and brain homovanillic acid in the rat.

Authors:  W H Chang; E K Yeh; W H Hu; Y T Tseng; M C Chung; H F Chang
Journal:  Biol Psychiatry       Date:  1986-04       Impact factor: 13.382

10.  Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection.

Authors:  E R Korpi; B H Phelps; H Granger; W H Chang; M Linnoila; J L Meek; R J Wyatt
Journal:  Clin Chem       Date:  1983-04       Impact factor: 8.327

View more
  5 in total

Review 1.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

3.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 5.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.